Having trouble accessing articles? Reset your cache.

Omapro omacetaxine mepesuccinate regulatory update

ChemGenex will delay a separate NDA submission for Omapro omacetaxine in third-line chronic myelogenous leukemia (CML) to 2H11 from year end 2010 to collect additional

Read the full 256 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE